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Abstract The neurotransmitter acetylcholine (ACh) plays a
critical role in brain circuits mediating motor control,
attention, learning and memory. Cholinergic dysfunction is
associated with multiple brain disorders including Alz-
heimer’s Disease, addiction, schizophrenia and Attention-
Deficit Hyperactivity Disorder (ADHD). The presynaptic
choline transporter (CHT, SLC5A7) is the major, rate-
limiting determinant of ACh production in the brain and
periphery and is consequently upregulated during tasks that
require sustained attention. Given the contribution of
central cholinergic circuits to the control of movement
and attention, we hypothesized that functional CHT gene
variants might impact risk for ADHD. We performed a
case-control study, followed by family-based association
tests on a separate cohort, of two purportedly functional
CHT polymorphisms (coding variant Ile89Val (rs1013940)
and a genomic SNP 3’ of the CHT gene (rs333229),
affording both a replication sample and opportunities to
reduce potential population stratification biases. Initial
genotyping of pediatric ADHD subjects for two purportedly
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DOI 10.1007/s11689-009-9033-8functional CHT alleles revealed a 2–3 fold elevation of the
Val89 allele (n=100; P=0.02) relative to healthy controls,
as well as a significant decrease of the 3’SNP minor allele
in Caucasian male subjects (n=60; P=0.004). In family
based association tests, we found significant overtransmis-
sion of the Val89 variant to children with a Combined
subtype diagnosis (OR=3.16; P=0.01), with an increased
Odds Ratio for a haplotype comprising both minor alleles.
These studies show evidence of cholinergic deficits in
ADHD, particularly for subjects with the Combined
subtype, and, if replicated, may encourage further consid-
eration of cholinergic agonist therapy in the disorder.
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Introduction
Attention deficit/hyperactivity Disorder (ADHD), as
described by the DSM-IV-TR (Diagnostic Statistical
Manual, 4
th edition, text revised, [1], is a psychiatric
disorder characterized by symptoms of inattention, hyper-
activity and impulsivity. ADHD is the most common
psychiatric disorder among children, with an estimated
prevalence of 3–10% and a 3–4 fold increased prevalence
in males. Although formally diagnosed in childhood, 60%
of these cases have been suggested to persist into adulthood
[2, 3]. ADHD subjects can exhibit predominantly inatten-
tive or hyperactive-impulsive symptoms, but also may
display a combined subtype, exhibiting elevations on both
symptom dimensions. Multiple studies have examined the
contributions of genetic factors to the development of
ADHD [4–6] with current models most consistent with a
complex polygenic disorder and a heritability estimated at
~80%.
Molecular genetic studies in patients with ADHD have
identified candidate genes that may contribute to the
pathophysiology of ADHD [6, 7]. Prominent focus has
centered on genes impacting dopamine and norepinephrine
functioning [8–11] due to their roles in governing
signaling in cognitive and motor circuits, as well as
being targeted by current pharmacotherapies [12, 13].
Less attention has been given to genes impacting acetyl-
choline (ACh) signaling as determinants of ADHD risk
[14, 15], despite the major role played by basal ganglia
cholinergic interneurons in movement control [16, 17]a n d
the activity of thalamic and cortical cholinergic pathways
that regulate sensory gating and attention [18, 19]. Thus,
tasks requiring sustained attention activate cortical cholin-
ergic neurotransmission, whereas muscarinic ACh receptor
(mAChR) antagonists (e.g. scopolamine) produce cogni-
tive and motor impairments in both animals and humans
[20, 21]. Notably, two cholinergic genes (CHRNA4 and
CHNRA7) that encode α4a n dα7 subunits of nicotinic
acetylcholine receptors, respectively, have been associated
with ADHD [22, 23].
A major determinant of cholinergic signaling capacity is
the presynaptic choline transporter (CHT) which transports
choline into cholinergic terminals to sustain ACh synthesis
[24, 25]. Genetic deletion of the mouse CHT gene results in
paralysis and early postnatal lethality, most likely arising
from an inability to sustain cholinergic signaling at the
neuromuscular junction. Depolarization of cholinergic neu-
rons in vitro elevates choline uptake (increase in Vmax)t h a ti s
supported by a translocation of CHT protein to the plasma
membrane [25–27]. Ex vivo measurements of CHT traffick-
ing in rat cortex following exposure to attention demanding
tasks also reveal elevated CHT surface expression [28].
The human high-affinity choline transporter gene
(hCHT, SLC5A7) is located on chromosome 2q12 and has
been demonstrated to be a source of genetic variation for
cholinergic traits [29, 30]. Okuda and colleagues reported
the identification of a common, nonsynonymous SNP
(+265 A/G; rs1013940) that encodes a substitution of
isoleucine for valine in position 89 (Ile89Val) of hCHT
transmembrane domain 3 [29]. In transfected cells, Val89-
containing CHT protein exhibits an ~50–60% maximal rate
of choline uptake as compared to Ile89 CHT despite normal
surface expression [29]. CHT heterozygous mice display
significant reductions in CNS ACh levels and muscarinic
receptors, as well as fatigue in sustained motor tasks [31].
The expression of a CHT hypomorph in a significant
fraction of humans (6% reported minor allele frequency)
makes the Val89 variant an exceedingly interesting candi-
date in imposing risk for disorders associated with
cholinergic deficits. Indeed, we recently described a
significant association of the Val89 variant with major
depression [32]. Another polymorphism, originally desig-
nated as a component of the CHT 3’UTR (+4067 G/T;
rs333229), here designated the 3’SNP (see Methods) has
been associated with altered cholinergic tone, as measured
by heart rate variability (HRV), and to altered corticolimbic
reactivity [33, 34].
In the current study, we hypothesized that functional
variation in CHT could impact risk for ADHD and thus
examined both the Ile89Val and the 3’SNP in 1) a case-
control study utilizing a community sample of DSM-IV
validated ADHD subjects versus a healthy control popula-
tion and 2) a within-family association study involving
parent-offspring trios, testing for association with both the
primary diagnosis (ADHD), as well as the two common
diagnostic subtypes. Here we provide evidence that genetic
variation in CHT significantly increases risk for ADHD,
particularly for children diagnosed with the Combined
subtype.
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Subjects: case-control study
ADHD subjects involved in our initial case-control study
were consented and enrolled at Vanderbilt University
Medical Center (VUMC), Nashville, TN, USA and the
University of Chicago Children’s Hospital, Chicago, IL,
USA. Subject ascertainment was performed under a
protocol approved by the Institutional Review Boards of
both institutions. The VUMC sample consisted of 50
unrelated and 10 affected sib pairs (n=63 subjects
genotyped; 81% male/19% female; 51% Cacasian/12%
African American) ranging from 6–17 years of age. The
Kiddie-SADS-Present and Lifetime Version [35] was used
to determine DSM-IV criteria for ADHD subtypes [36].
The University of Chicago cohort (n=37 subjects geno-
typed; 70% male/30% female; 86% Caucasian/14% African
American) consisted of a subset of unrelated children who
had participated in an earlier pharmacogenetic study [37].
All subjects completed a semi-structured diagnostic inter-
view and met DSM-IV criteria for ADHD. Children were
excluded if they carried a diagnosis of autism or other brain
disorders such as mental retardation. The Vanderbilt
University control cohort consisted of 290 subjects,
between 18–45 years of age that displayed no clinically
significant abnormality based upon medical history, phys-
ical examination and routine laboratory testing.
Subjects: within-family association study
Clinic-referred sample Four hundred and three children
from 251 families were consented and enrolled from two
sites, Atlanta, Georgia and Tucson, Arizona, USA (see
Suppl Table 1 for details). The Emory University and
University of Arizona Institutional Review Boards
reviewed and approved the assessment procedures utilized.
At the Atlanta site, subjects were recruited through the
Center for Learning and Attention Deficit Disorders
(CLADD) at the Emory University School of Medicine
and the Emory University Psychological Center. Both
clinics specialize in the assessment of childhood external-
izing disorders such as ADHD, Oppositional Defiant
Disorder (ODD), Conduct Disorder (CD) and learning
disorders. At the Tucson site, subjects were recruited
through a group psychiatric practice. Probands and their
siblings between the ages of 4 and 18 (M=10.7, SD=3.9)
were then recruited to participate in the current study. Any
child previously diagnosed with autism, traumatic brain
injury, or neurological conditions (e.g., epilepsy) was
excluded from the study, as were children with IQs <75.
Any other diagnosis previously assigned to a child
remained confidential and did not influence inclusion in
the study. Control subjects were also recruited from sites in
Atlanta, Georgia and Tucson, Arizona. Subjects recruited at
the Atlanta site represent a subsample of the Georgia Twin
Registry, a sample of twins born between 1980 and 1991
recruited via birth records from the general population of
Georgia. Twin families were originally recruited by mail to
participate in a questionnaire-based study of childhood
psychopathology. A subset of these families was contacted
by phone to participate in a follow-up lab study of
temperament and cognitive dev e l o p m e n tt h a ti n c l u d e d
DNA collection. Subjects from the Tucson site were drawn
from the general population.
Parental ratings were obtained whenever possible for
each child using the Emory Diagnostic Rating Scale
(EDRS) [38], a symptom checklist developed to assess
symptoms of major DSM-IV childhood psychiatric disor-
ders such as ADHD, ODD, and CD. Because some children
were being treated with medication, parents were asked to
rate the status of the child’s symptoms when off medica-
tion. Parents rated each symptom on a 0–4 scale, with a
score of 0 indicating that the symptom is “not at all”
characteristic of the child and a score of 4 indicating that
the symptom is “very much” characteristic of the child.
Inattentive and hyperactive-impulsive symptom scores were
generated by averaging the scores for the 9 items that
constitute each symptom dimension. For the purposes of
making ADHD and subtype diagnoses, ratings ≥2 for each
symptom indicated that a symptom was present. In the case
of discrepant parent ratings for a specific symptom, the
symptom was considered present if endorsed (i.e., rated ≥2)
by the mother when assigning ADHD diagnoses and the
mother’s score was then used when creating symptom
scales. Consistent with previous studies, mother and father
ratings showed moderate agreement (r=.76 for inattentive
symptoms and r=.69 for hyperactive-impulsive symptoms)
[39]. Questionnaire-based diagnoses of ADHD and its
constituent subtypes were assigned by applying DSM-IV
symptom thresholds to each of the ADHD symptom
dimensions. An earlier study demonstrated that the EDRS
yielded diagnostic rates in a control population that were
similar to the prevalence rates described in the DSM-IV
[40]. The internal consistencies of the 9 hyperactive-
impulsive symptoms and the 9 inattentive symptoms were
independently evaluated in the clinic-referred and control
samples to ensure acceptable reliabilities (values ranged
from α=.85–.96).
Genotyping
DNA was collected from either buccal samples or from
whole blood and extracted using a commercial DNA
isolation kit (Gentra systems, Minneapolis, MN) as previ-
ously described [41]. An allelic discrimination assay was
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Research DNA Resources Core using TaqMan
® SNP
Genotyping Assay reagents (Applied Biosystems, Inc).
Four nanograms (ng) of DNA (some samples had been
subjected to one round of genomic amplification (Roche)
with no evidence of altered SNP calls) was used as template
in reactions containing 1X TaqMan
® Universal PCR Master
Mix and, for CHT Ile89Val (rs1013490), 900 nM forward
(5’-TGTACCAGGTTATGGCCTAGCTT-3’) and reverse
(5’-ACTGAGATTTGCACTTTCACTTACCT-3’) amplifi-
cation primers, 200 nM VIC
® (5’-CAGGCACCAATTG
GATA-3’)a n dF A M
® (5’-AGGCACCAGTTGGATA-3’)
dye-labeled probes or, for the CHT 3’SNP (3’SNP,
rs333229), forward (5’-GTGGACACACTTCTGGAGAT
TATACATTT-3’) and reverse (5’-GTCCACGGGC
CCTAATATTATATTCT-3’) and 200 nM VIC
® (5’- CTC
TTAATAATTCCCCCCCACACT-3’) and FAM
® (5’-C T
CTTAATAATTCACCCCACACT-3’) dye-labeled probes.
The 3’SNP has been previously described as a “3’UTR
SNP” [33, 34] but our current genomic analyses place the
variant 3’ of predicted polyadenylation sites and could
not be identified with deposited ESTs. Thermal cycling
(95°C for 10 min, followed by 50 cycles of 92°C for 15
sec and 60°C for 1 min) and product detection were
accomplished using the ABI 7900HT Real-Time PCR
System (ABI).
We conducted quality control analyses of the CHT SNP
genotype data in our family samples. The call rate in our
sample was 93% for the Ile89Val SNP and 94% for the
3’SNP. Reliability of the genotyping was assessed by
examining the concordance of genotypes of twins within
MZ twin pairs, in which there were no disagreements
between the genotypes for the Ile89Val SNP (an allelic
discordance rate=0%, N=68 alleles) and only one disagree-
ment for the 3’SNP (an allelic discordance rate=1.4%,
N=74 alleles). There were no Mendelian errors in the
genotyping of the Ile89Val SNP whereas there were 8 errors
for the 3’SNP, yielding a Mendelian error rate=0.9%.
Data analyses
Crosstab analyses using SPSS version 15 (SPSS, Inc.,
Chicago, IL) were conducted for quality control analyses
that included measures of genotype reliability and MZ twin
agreement for genotypes. Call rates, Mendelian error rates,
and exact Hardy Weinberg Equilibrium (HWE) tests and
p-values were also estimated using the program PEDSTATS
[42]. For the case-control studies, genotype call rates
were found to be within HWE and significance deter-
mined using the χ
2-test (results shown below). To protect
against the possibility of interpreting a spurious associa-
tion as substantive, significant results from the case-
control analyses were then followed-up in an independent
sample using family-based tests of association with the
associated alleles from the case-control analyses designat-
ed as the ‘risk’ alleles.
Extensions of the Transmission Disequilibrium Test (i.e.,
TDT) [43] that are applicable to both categorical and
continuous variables and tests of moderation [44–47] were
used for family-based analyses of association and linkage.
Such analyses have the advantage of robustness against
possible population stratification effects that may bias the
results of traditional case-control comparisons or other
population-based analyses of association. A unifying
approach to family-based association tests (FBATs) has
been developed and implemented in the software packages
FBAT and PBAT. Derived from the TDT, the FBAT and
PBAT approaches have been extended to incorporate both
intact and missing parental genotypes without introducing
bias as well as affected and unaffected siblings and
extended pedigrees [45, 48–50]. The FBAT and PBAT
software packages also allow for the contribution of
unaffected control subjects in the calculation of the FBAT
test statistic. By specifying an offset equal to the population
prevalence of the disorder, the FBAT and PBAT software
makes use of genotypic transmissions in case and control
subjects by contrasting the number of transmissions of a
specific allele in the case population with the number of
non-transmissions of that allele in the control population
[45]. As such, both case and control subjects can be utilized
within a TDT framework. Specifying the offset also serves
to minimize the variance of the test statistic and increase
statistical power [51]. Thus, the prevalence of the ADHD
diagnosis and the respective subtypes in the control sample
as assessed by the EDRS were used as offset values in the
current study.
We also used a recently developed extension of the TDT
[52] to test a priori hypotheses for the contrasts among the
diagnostic subtypes. In this method, transmissions of a
particular allele from heterozygous parents to children with
a subtype of interest are contrasted with transmissions to
children who have the other subtypes or who are unaffect-
ed. We implemented this test within the FBAT/PBAT
analytic framework to test for the association of CHT SNPs
with the Inattentive and Combined ADHD subtypes (the
Hyperactive-Impulsive subtype was not tested due to small
sample size). All of the analyses conducted in FBAT and
PBAT yield a Z statistic that was used in hypothesis
testing and which was converted into the effect size
index R
2 (i.e., proportion of the variance accounted for)
using the formula Z
2 /N ,w h e r eN=the number of
informative families. Odds Ratios (OR) were calculated by
first converting the R
2 value into the effect size Cohen’sd
using the formula d=(2 * R)/ √(1 - R
2)[53], and then
calculating an OR using the formula e
( 1 . 8 1*d )described
by Chinn [54].
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Case-control study of CHT SNPs in ADHD
Our initial evaluation of the association of CHT SNPs in
ADHD was performed as a simple case-control design with
affected subjects drawn from prior Vanderbilt and Univer-
sity of Chicago studies [9, 11, 37]. The mean age of the
Vanderbilt/Chicago sample was 10.5±0.3 years and was
76% male, 24% female with mostly Caucasian (81%)
versus African-American (19%) subjects. Controls subjects
were drawn from a panel of healthy controls with no
medical diagnoses, originally recruited for cardiovascular
studies. The mean age of the control sample was 28±
7.7 years and was 42% male, 58% female with both
Caucasian (44%) and African-American (56%) subjects.
Owing to significant ethnic variation evident in the CHT
Val89 variant (NCBI dbSNP, build 129; refSNP ID:
rs1012940; GenBank accession no.: NT005224.10), we
restricted our case-control analyses to the Caucasian subset
of this panel.
Genotypes for both Ile89Val and 3’SNP polymorphisms
were reliably obtained and found to be in Hardy-Weinberg
equilibrium in both case (Ile89Val, p=0.99; 3’UTR, P=
0.75) and control groups (Ile89Val, P=0.52; 3’SNP, P=
0.93). The minor allele for the Val89 marker has been
previously reported at an allele frequency of 6% in a
nonclinical sample of Ashkenazi Jewish subjects [29],
which is identical to the allele frequency we obtained in
our Caucasian control samples (Table 1). The CHT 3’SNP
major allele has been reported as 77% in healthy Cauca-
sians [33] and was also comparable to our findings with
Caucasian control DNAs (73%, Table 1). Independent
studies indicate that the 3’SNP major allele and the Val89
minor allele are associated with reduced choline uptake or
cholinergic function [29, 34]. In the Vanderbilt/Chicago
ADHD panel, the allele frequency for the CHT 3’SNP
major allele was slightly elevated (79%), though this
change did not reach statistical significance. Further
examination of the CHT 3’SNP allele frequencies in
Caucasian and Caucasian male-only groups versus matched
controls showed a significant shift in allele distribution
that did not differ between the diagnostic subtypes
(Caucasian, 84% major allele, P=0.008; Caucasian-male
only, 87%, P=0.004). These findings support the associ-
ation of reduced cholinergic tone with a diagnosis of
ADHD in Caucasian subjects. Similarly, the allele
frequency of the hypomorphic Val89 CHT variant were
significantly elevated (12%) compared to that (6%) found
in our healthy controls (P=0.023). Further examination of
Val89 allele frequencies in Caucasian or Caucasian male-
only groups versus matched controls revealed an even
greater increase in both the Inattentive (Caucasian, 15%;
P=0.03; Caucasian-male only, 17%; P=0.02) and Com-
bined (Caucasian, 14%; P=0.03; Caucasian-male only,
15%; P=0.03) subtypes (Table 1).
Family-based association analyses of CHT SNPs in ADHD
The study sample used for our within-family association
analyses represents an expansion of that reported in
previous publications (see Suppl Table 1 for complete
sample characteristics) [38, 55]. Our sample comprised 269
boys (67%) and 134 (33%) girls, with an ethnic back-
ground of 78% Caucasian, 10% African-American, 2%
Hispanic, 1% Asian, and 8% of mixed ethnicity. Two
hundred of the 251 probands met criteria for a DSM-IV
ADHD diagnosis with 70 children (35%) diagnosed with
the predominately Inattentive subtype, 12 (6%) with the
predominately Hyperactive-Impulsive subtype, and 118
(59%) with the Combined subtype. These subtype preva-
lence rates are consistent with those reported in the
literature which indicate that the Combined subtype is
1.5 to 2 times more common than the Inattentive subtype
in clinic-referred samples [56, 57]. Thirty-six of the 152
siblings that participated in the study met criteria for
ADHD. Thirteen (36%) were diagnosed with the predom-
inately Inattentive subtype, 10 (28%) with the predomi-
nately Hyperactive-Impulsive subtype, and 13 (36%) with
the Combined subtype.
As shown in Suppl Table 1, control children differed
from clinic-referred children with respect to age, gender,
and ethnicity (P-values<.05). Control subjects ranged
in age from 6 to 18 years (M=12.9, SD=2.6), included
138 boys (58%) and 98 girls (42%), and their ethnic
background was 92% Caucasian, 2% African-American,
2% Asian, and 4% Hispanic. Because control subjects
were drawn from the general population, a certain percent-
age of these children were expected to exhibit clinically
significant symptoms of ADHD. Forty-five met crite-
ria for the ADHD diagnosis. Twenty-four (53%) were
diagnosed with the predominately Inattentive subtype,
8 (18%) with the predominately Hyperactive-Impulsive
subtype, and 13 (29%) with the Combined subtype. These
subtype prevalence rates are consistent with those
reported in the literature that indicate the Inattentive
subtype to be approximately twice as common as the Com-
bined subtype in community samples [58, 59]. Hardy-
Weinberg equilibrium (HWE) was evaluated, excluding
individuals of African-American ethnic background given
the pronounced differences in allele and genotype fre-
quencies for CHT SNPs between individuals of European
and African descent (International HapMap Project,
2005). There was no significant departure from HWE
for either the Ile89Val (P=1.00) or the 3’SNP (P=.066) in
founders.
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J Neurodevelop Disord (2009) 1:252–263 257As shown in Tables 2 and 3, in our family-basedanalyses
of association of the overall ADHD diagnosis with the
Ile89Val or 3’SNP using FBAT, we found no evidence for
association with either SNP across additive, dominant, or
recessive genetic models, regardless of whether only affected
caseswereanalyzedorwhetheraffectedcaseswerecontrasted
with unaffected controls (i.e., the minimum P=0.347 for the
3’SNP under a dominant model contrasting transmission in
affected cases versus unaffected controls). As shown in
Table 2, however, there was a significant association between
the Val89 allele and the Combined subtype, which was
strongest under additive and dominant models when the
Combined subtype was contrasted with no diagnosis and all
other subtypes (additive: Z=2.19, one-tailed P=0.014,
R
2=.09, OR=3.16; dominant: Z=1.97, one-tailed P=0.024,
R
2=.07 OR=2.79).
We next conducted similar family-based association
analyses of ADHD and its diagnostic subtypes with
haplotypes comprising both CHT SNPs (Table 4). Linkage
disequilibrium between the two markers was virtually
absent (D’=.04. R
2=.01). For the overall diagnosis of
ADHD, as well as the Combined and Inattentive subtypes,
we conducted an omnibus test of association for all
haplotypes as well as a targeted test of and when
significant, followed this up by determining which specific
haplotype was responsible for the observed association the
subtype comprising all possible haplotypes. In all haplotype
tests, we contrasted transmissions in ADHD cases versus
unaffected controls or transmissions in the Combined or
Inattentive subtypes versus unaffected controls and all other
subtypes. All of the haplotype tests for either the ADHD
diagnosis or the Inattentive subtype were non-significant. In
contrast, the omnibus tests yielded a significant association
with the Combined subtype under an additive model
(Z=8.48, P=.037) and a trend towards an association under
a dominant model (Z=8.16, P=0.086) with the haplotype
comprising both Ile89Val and 3’SNP minor alleles showing
the strongest associations (additive model: Z=2.65,
P=0.008, R
2=.048, OR =2.25; dominant model: Z=2.65,
P=0.008, R
2=.069, OR =2.68).
Discussion
To our knowledge, no investigations of CHT gene variation
in the context of ADHD have been reported. Possibly,
modest alterations in CHT expression or function might
have no detectible influence on physiology and behavior.
However, studies with CHT heterozygous knockout mice
reveal a significant reduction in brain ACh levels, as well as
reduced motor endurance and locomotor responsiveness to
cholinergic antagonist administration [31]. Human studies
reveal two CHT polymorphisms with a likely functional
impact on cholinergic signaling. The Val89 variant exhibits
reduced choline transport function compared to the Ile89
variant in transfected cells [29] and has been associated
with major depression [32]. A second purportedly func-
tional SNP, located 3’ of predicted CHT polyadenylation
sites, is associated with altered autonomic cholinergic tone
as well as cortical reactivity and depression [33, 34]. Given
the prominent role of thalamic and cortical cholinergic
signaling for sensory gating and sustained attention [60,
61], we hypothesized that one or more, or both, of the CHT
variants might contribute risk for ADHD. Indeed, with our
Vanderbilt/Chicago ADHD cohort, we observed an in-
creased frequency of the Val89 CHT hypomorph as
compared to published allele frequencies and our own
healthy control population [29]. As a check on the allele
frequencies our healthy control panel, we also genotyped
the Ile89Val polymorphism on a commercial panel (Coriell)
and found a comparable frequency for Caucasians (9%) and
Caucasian males (8%), significantly below the allele
Table 2 FBAT test for association of CHT Ile89Val (rs1013940) SNP with ADHD and diagnostic subtypes
Diagnosis N ADHD (offset=.14) Combined (offset=.06) Inattentive (offset=.08)
ZP R
2 OR Z P R
2 OR Z P R
2 OR
Model
Additive 51 -.903 .817 .016 0.63 0.802 .211 .012 1.50 -2.406 .992 .114 0.28
awith unaffecteds -.004 .502 .00 1.00 2.189 .014 .092 3.16 -0.834 .798 .013 0.66
Dominant 51 -.842 .800 .014 0.65 0.574 .283 .006 1.33 -2.314 .990 .105 0.29
awith unaffecteds 0.090 .464 .00 1.05 1.969 .024 .074 2.79 -0.659 .745 .009 0.71
Recessive 6 -.428 .666 .03 0.53 0.938 .174 .143 4.39 -0.990 .839 .163 0.20
awith unaffecteds -.285 .612 .013 0.66 1.262 .103 .26 8.54 -0.736 .769 .088 0.32
N=number of informative families, all tests were interpreted using a one-tailed p-value
aModels in which ADHD cases were contrasted with unaffected individuals, or in which individuals with the target ADHD subtype were
contrasted with both unaffected individuals and individuals diagnosed with the other ADHD subtypes
258 J Neurodevelop Disord (2009) 1:252–263frequency of our ADHD subjects. Depending on gender, the
elevation we observed in Val89 frequency in our ADHD
subjectsisequivalentto, or above,thatwhich wereported ina
major depression cohort [32]. Depression and ADHD exhibit
significant comorbidity [62, 63]. The higher rate of suicide in
ADHD subjects exhibiting depression [64, 65]w a r r a n t sa n
assessment of whether altered cholinergic tone represents a
common pathway to ADHD/depression comorbidity.
Although we made an effort to constrain our case-control
analysis by ethnicity and gender, such designs are subject to
unknown population stratifications that can lead to false
positive (or negative) results. We thus sought to gain further
insight into the impact of the CHT gene variants in ADHD
via within-family association analyses of both alleles
individually and in combination using a parent-offspring
trio design in a large, more well-defined ADHD cohort. We
did not constrain our analyses by ethnicity or gender in
transmission studies to maintain the largest sample size
possible and increase power. We observed preferential
transmission of the CHT 89Val allele with the Combined
subtype of ADHD using both additive and dominant
models. These findings indicate that having 1 or 2 copies
of the risk allele increases the likelihood of a Combined
ADHD diagnosis in an additive fashion. Although other
coding variants in neurotransmitter transporters are known
to act dominantly that could be explained by dominant-
negative interactions [66–68], similar information is not yet
available for the CHT Val89 variant. To date, the Val89
CHT variant has only been studied in vitro in a parallel
comparison with the Ile89 variant, and not following
Table 3 FBAT tests for association of the CHT 3’SNP (rs333229) with ADHD and diagnostic subtypes
Diagnosis N ADHD (offset=.14)* Combined (offset=.06) Inattentive (offset=.08)
ZP R
2 OR Z P R
2 OR Z P R
2 OR
Model
Additive 125 -.470 .681 .002 0.86 -1.004 .684 .008 0.72 -.411 .659 .001 0.88
awith unaffecteds -.478 .684 .002 0.86 -1.001 .683 .008 0.72 -.285 .612 .001 0.91
Dominant 35 0.179 .479 .00 1.12 0.049 .480 .00 1.03 -.157 .562 .00 0.91
awith unaffecteds 0.393 .347 .004 1.27 0.314 .376 .003 1.21 0.130 .448 .00 1.08
Recessive 114 -.661 .746 .004 0.80 -1.235 .892 .013 0.66 -.408 .658 .001 0.87
awith unaffecteds -.797 .787 .006 0.76 -1.366 .914 .016 0.63 -.422 .663 .002 0.87
N = number of informative families, all tests were interpreted using a one-tailed p-value
aModels in which ADHD cases were contrasted with unaffected individuals, or in which individuals with the target ADHD subtype were
contrasted with both unaffected individuals and individuals diagnosed with the other ADHD subtypes
Table 4 Association of the CHT Val89 and 3’SNP minor allele with ADHD and the combined and inattentive predominant diagnoses
Diagnosis ADHD (offset=.14)* Combined (offset=.06) Inattentive (offset=.08)
χ
2 /Z P R
2 OR χ
2 /Z P R
2 OR χ
2 /Z P R
2 OR
Model
a
Additive [Multimarker] 0.457 .324 -.906 .817 -.233 .592
Omnibus χ
2 Test 0.855 .836 8.482 .037 2.396 .494
Test of risk haplotype 0.742 .458 .002 1.18 2.653 .008 .048 2.25 0.412 .681 .00 1.09
Dominant [Multimarker] 0.777 .219 0.184 .427 0.861 .195
Omnibus χ
2 Test 1.063 .900 8.159 .086 3.812 .432
Test of risk haplotype 0.742 .458 .003 1,21 2.653 .008 .069 2.68 0.412 .681 .001 1.11
Recessive [Multimarker] -0.362 .641 -1.771 .962 -.558 .712
Omnibus χ
2 Test 0.661 .882 4.764 .190 1.563 .668
Test of risk haplotype NA NA NA NA NA NA NA NA NA NA NA NA
NA indicates that there were too few informative families to test the target haplotype
aIn all models, ADHD cases were contrasted with unaffected individuals, or individuals with the target ADHD subtype were contrasted with both
unaffected individuals and individuals diagnosed with the other ADHD subtypes. Omnibus χ
2 tests of all 4 haplotypes had 3 degrees-of-freedom
and were evaluated using a two-tailed p-value, Z tests of the risk haplotype (i.e., the G-C haplotype comprising the minor alleles for both CHT
SNPs) had 1 degree-of-freedom and were evaluated using a two-tailed p-value
J Neurodevelop Disord (2009) 1:252–263 259co-expression studies that could test the possibility of
homo-oligomerization, as seen for other transporters
[69–71]. Clearly, further in vitro studies are needed to
establish the genetic model underlying the impact of the
Val89 SNP in ADHD.
The preferential transmission of the CHT Val89 hypo-
morph to the Combined subtype in the additive model may
reflect the importance of cholinergic transmission in
modulating fundamental aspects of both motor control and
attention [72, 73]. On neuroanatomical grounds, patients
with reduced CHT activity should have cholinergic deficits
at both cortical and subcortical levels which could produce
both inattentive and hyperactivity symptoms. Cholinergic
interneurons within the striatum participate in extrapyrami-
dal motor control [74] and alterations in the balance of
cholinergic/dopaminergic signaling in this nucleus is
implicated in a spectrum of motor abnormalities from
hyperactivity and motor tics to dystonia and Parkinson’s
disease [75]. Consistent with these ideas, disruptions in
cholinergic transmission produce deficits in attention and
can trigger hyperactivity [76, 77]. Experimentally-induced
cortical and striatal reductions in ACh content produce
hyperlocomotion and other motor dysfunctions [78, 79].
Similarly, mice lacking the M1 muscarinic receptor exhibit
an increase in locomotor activity and altered dopamine
signaling [77]. Consistent with our findings on CHT, Lee et
al. recently reported an association of two markers in exon
2 and intron 2 of the α4 subunit of the nAChR that are
selectively transmitted to subjects with the Combined
subtype of ADHD [80]. Currently, medications for ADHD
predominantly target catecholaminergic signaling and are
not prescribed differently based on diagnostic subtype. Our
findings, if reproduced, encourage further consideration of
cholinergic agonist therapy as well as evaluation of whether
cholinergic modulation is most beneficial for subjects
presenting with both motor and attention symptoms.
Our studies also explored a potential impact of the
3’SNP variant in CHT. Although the overall association of
the 3’SNP minor allele to ADHD in our case-control
paradigm was non-significant, a significant increase in the
major allele was evident when our data set was limited to
male Caucasians. We do not know the basis for the
ethnicity and gender effects on allele frequencies, nor
whether they relate to the male predominance in ADHD
diagnoses. Presently, the functional impact of this 3’SNP at
the level of CHT gene expression is unknown, but may
serve as a downstream repressor of transcription [81]o rb e
in linkage disequilibrium with one or more other functional
variants. Alternatively, the variant may be in linkage
disequilibrium with another variant in or near the CHT
gene impacting transporter expression. Healthy patients
carrying the 3’SNP minor allele demonstrate an increase
heart rate variability that is associated with increased
parasympathetic tone [33]. Our case-control findings of a
decrease in the 3’SNP minor allele is, therefore, most
consistent with reduced cholinergic function? in ADHD.
In our within-family association study, although we
observed no association between the overall ADHD
diagnosis or any diagnostic subtype with the 3’SNP on its
own, we detected a highly significant association of a two
locus haplotype comprised of the CHT Val89 allele and the
3’SNP minor allele. This finding is somewhat surprising
given that these two alleles are predicted to support reduced
Val89) and elevated (3’SNP T allele) cholinergic tone,
respectively. These two polymorphisms are not in linkage
disequilibrium and thus it is possible that at risk subjects
may carry both minor alleles on the same transcript. If the
CHT Val89 protein variant exhibits a dominant-negative
action on Ile89 protein, elevations in the Val89 protein
made possible by elevations in CHT mRNA levels driven
by the 3’SNP minor allele could explain our family-based
association findings. Clearly, however, such conclusions are
speculative given 1) the lack of study of oligomerization of
CHT proteins, 2) the uncertain mechanistic status of the
3’SNP, and 3) the limited power of our analysis due to
inherent reductions in sample size arising with selection of
multiple gene variants, as well as subdivision of diagnoses
by phenotypic subclasses.
A number of reports have described genome wide
linkage or association studies in ADHD [82–85]. Many
loci do not replicate across studies, though chromosomal
regions 5p13, 14q12 and 17p11 have been implicated in
multiple studies [86, 87]. The SLC5A7 gene is located on
chromosome 2q12, and has not to date been identified in
published genome wide studies in ADHD. Genome wide
studies face daunting power issues due to large number of
tests performed. Our study was focused on CHT from the
neurobiological perspective of alterations in cholinergic
tone contributing to motor and cognitive behavioral
domains altered in ADHD. Future studies with a larger
number of markers in and adjacent to the SLC5A7 locus
may provide further insight into the contribution of the
CHT gene to ADHD.
Despite the potential of the reported findings to further
our understanding of the relation between the CHT gene
and ADHD, it should be noted that a number of statistical
tests were conducted in the present study, but due to the
modest sample size, corrections were not made for multiple
testing. Nonetheless, specific steps were taken to protect
against interpreting a spurious association as substantive.
The most stringent step was the inclusion of two indepen-
dent samples and two complementary research designs and
analytic methods, thus providing a follow-up sample and
more rigorous family-based association tests with which to
confirm the original case-control association findings. Thus
for all analyses conducted in the follow-up sample,
260 J Neurodevelop Disord (2009) 1:252–263directional predictions were made regarding potential
associations between the CHT gene SNPs and ADHD
phenotypes to ensure that only associations with the alleles
identified in the case-control analyses were interpreted as
significant in the follow-up analyses. Despite the precau-
tions taken, some possibility that the reported findings
represent a spurious association remains, and future studies
replicating these results are necessary.
In summary, the current study provides evidence of both
association and preferential transmission of the CHT Val89
variant to the ADHD Combined subtype, alone and in
combination with the minor allele of the CHT 3’SNP
polymorphism. Future studies, besides seeking further
replication on independent ADHD samples, should exam-
ine directly the functional role of these variants on
cholinergic neurotransmission in humans in vivo as well
as explore the Combined subtype as a preferential subgroup
for cholinergic therapeutics.
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